Retatrutide: The Triple-Hormone Drug That Could Make Today's GLP-1s Look Like a Starting Point

Semaglutide (Wegovy) targets one hormone. Tirzepatide (Zepbound) targets two. Retatrutide — nicknamed "Triple G" — targets three: GLP-1, GIP, and glucagon. And the weight loss numbers are in a different league.

The Clinical Trial Results

In clinical trial results reported in December 2025, retatrutide produced average weight loss of up to 29% of body weight after 68 weeks in patients with knee osteoarthritis. For a 250-pound person, that translates to roughly 71 pounds lost.

New results released in March 2026 for type 2 diabetes patients showed:

• HbA1c reduction of 1.7–2.0% at 40 weeks (exceeding Mounjaro's results)
• Weight loss of up to 17% in diabetes patients (about 37 lbs) — notably, diabetes patients typically lose less weight on GLP-1s than non-diabetes patients
• The drug was also associated with significant reductions in knee pain in the osteoarthritis study

How Three Targets Beat Two

Each hormone target contributes differently:

• GLP-1 — Suppresses appetite, slows gastric emptying, improves blood sugar. The same mechanism used by Wegovy and Ozempic.
• GIP — Works synergistically with GLP-1 to enhance insulin sensitivity and fat metabolism. This is what tirzepatide adds over semaglutide.
• Glucagon — The new addition. Increases energy expenditure (calorie burning), promotes fat breakdown in the liver, and may help preserve lean muscle mass during weight loss.

The glucagon component is particularly significant because it addresses one of the biggest concerns about current GLP-1 medications: the loss of lean muscle mass during rapid weight loss. By boosting energy expenditure, glucagon may help shift the body's weight loss toward fat rather than muscle.

When Will It Be Available?

Retatrutide is currently in phase 3 clinical trials. Based on the typical regulatory timeline, an FDA approval could come in late 2027 or 2028. That's still years away, but the data so far has been strong enough that Eli Lilly is investing heavily in the development program.

What to Do in the Meantime

If you're waiting for the "perfect" weight loss drug, consider this: the medications available today — semaglutide and tirzepatide — produce clinically significant weight loss of 15–22%. A 200-pound person losing 15% still loses 30 pounds. The evidence clearly shows that starting treatment now with available medications is better than waiting for future options.

When retatrutide eventually arrives, patients who are already on GLP-1 treatment will likely have the option to switch. Starting now builds the habits, medical history, and provider relationships that make future transitions smoother.